Incidence and risk factor analysis of neovascular glaucoma following vitrectomy in patients with proliferative diabetic retinopathy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
19
08
2024
accepted:
17
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
To investigate the incidence and risk factors for neovascular glaucoma (NVG) after vitrectomy in patients with proliferative diabetic retinopathy (PDR). Patients were categorized into two subgroups based on their treatment regimen: one group received vitrectomy only (Group 1), while the other received combined phacovitrectomy (Group 2). A comparative analysis was conducted to evaluate the distinguishing characteristics of the two groups. Kaplan-Meier survival analysis was used to determine the incidence of NVG following surgery. Furthermore, multivariate analysis using the Cox proportional hazards model was conducted to identify the risk factors associated with the development of NVG after surgery. A total of 484 eyes of 484 patients were included in the study. When comparing Group 1 with Group 2, a significant difference was observed in the occurrence of NVG. In Group 1, there were 10 cases of NVG (3.9%), whereas 29 cases of NVG occurred in Group 2 (12.71%). Male sex, high preoperative intraocular pressure (IOP), and combined phacovitrectomy were found to be associated with the occurrence of NVG following phacovitrectomy. Higher creatinine levels had a protective effect in preventing the development of NVG. Male sex, high preoperative IOP, and combined phacovitrectomy were associated with a high incidence of NVG. Explore strategies to prevent NVG is important when performing combined phacovitrectomy in patients with PDR.
Identifiants
pubmed: 39341897
doi: 10.1038/s41598-024-73395-8
pii: 10.1038/s41598-024-73395-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22490Informations de copyright
© 2024. The Author(s).
Références
Berrocal, M. H., Acaba, L. A. & Acaba, A. Surgery for diabetic eye complications. Curr. Diab Rep. 16, 1–7 (2016).
doi: 10.1007/s11892-016-0787-6
Wahab, S. & Hargun, L. D. Combined phacoemulsification, vitrectomy and endolaser photocoagulation in patients with diabetic retinopathy and cataract. J. Coll. Phys. Surg. Pak.. 24(10), 736–739 (2014).
Yokota, R. et al. Comparison of microinsicion vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy. Jpn. J. Ophthalmol. 59, 288–294 (2015).
doi: 10.1007/s10384-015-0396-y
pubmed: 26202442
Zhang, Z-H. et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am. J. Ophthalmol. 156(1), 106–115 (2013). e102.
doi: 10.1016/j.ajo.2013.02.008
pubmed: 23791371
Enaida, H. et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina. 23(6), 764–770 (2003).
doi: 10.1097/00006982-200312000-00003
pubmed: 14707824
Chalam, K. V. & Shah, V. A. Optics of wide-angle panoramic viewing system–assisted vitreous surgery. Surv. Ophthalmol. 49(4), 437–445 (2004).
doi: 10.1016/j.survophthal.2004.04.010
pubmed: 15231400
Sakamoto, M., Hashimoto, R., Yoshida, I., Ubuka, M. & Maeno, T. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clin. Ophthalmol. 2323–2329. (2018).
Liang, X. et al. Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with diabetic retinopathy: an observational study. Diabetes Ther. 10, 1801–1809 (2019).
doi: 10.1007/s13300-019-0644-0
pubmed: 31321746
pmcid: 6778559
Goto, A. et al. Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. J. Glaucoma. 22(7), 572–576 (2013).
doi: 10.1097/IJG.0b013e31824d514a
pubmed: 22407392
Kwon, J., Jee, D. & La, T. Y. Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. Medicine. 96(10), e6263 (2017).
doi: 10.1097/MD.0000000000006263
pubmed: 28272234
pmcid: 5348182
Tseng, H-Y., Wu, W-C. & Hsu, S-Y. Comparison of vitrectomy alone and combined vitrectomy, phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy. Kaohsiung J. Med. Sci. 23(7), 339–343 (2007).
doi: 10.1016/S1607-551X(09)70419-X
pubmed: 17606428
Silva, P. S. et al. Visual outcomes from pars plana vitrectomy versus combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in patients with diabetes. Retina. 34(10), 1960–1968 (2014).
doi: 10.1097/IAE.0000000000000171
pubmed: 24830822
Wang, S. et al. Influencing factors of low vision 2 years after vitrectomy for proliferative diabetic retinopathy: an observational study. BMC Ophthalmol. 23(1), 309 (2023).
doi: 10.1186/s12886-023-03071-4
pubmed: 37430223
pmcid: 10331988
Sun, D. et al. The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy. Eur. J. Ophthalmol. 31(6), 3057–3067 (2021).
doi: 10.1177/1120672120980686
pubmed: 33334171
Summanen, P. Neovascular glaucoma following vitrectomy for diabetic eye disease. Acta Ophthalmol. 66(1), 110–116 (1988).
doi: 10.1111/j.1755-3768.1988.tb08544.x
SooHoo, J. R., Seibold, L. K. & Kahook, M. Y. Recent advances in the management of neovascular glaucoma. Paper presented at: Sem Ophthalmol. (2013).
Stefánsson, E. Physiology of vitreous surgery. Graefes Arch. Clin. Exp. Ophthalmol. 247, 147–163 (2009).
doi: 10.1007/s00417-008-0980-7
pubmed: 19034481
Smith, D. W., Lee, C-J. & Gardiner, B. S. No flow through the vitreous humor: how strong is the evidence? Prog. Ret. Eye Res. 78, 100845 (2020).
doi: 10.1016/j.preteyeres.2020.100845
Maeda, N. & Tano, Y. Intraocular oxygen tension in eyes with proliferative diabetic retinopathy with and without vitreous. Graefes Arch. Clin. Exp. Ophthalmol. 234, S66–S69 (1996).
doi: 10.1007/BF02343050
pubmed: 8871152
Chen, H-J., Ma, Z-Z., Li, Y. & Wang, C-G. Change of vascular endothelial growth factor levels following vitrectomy in eyes with proliferative Diabetic Retinopathy. J. Ophthalmol. 2019. (2019).
Kovacs, K. et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest. Ophthalmol. Vis. Sci. 56(11), 6523–6530 (2015).
doi: 10.1167/iovs.15-16793
pubmed: 26447988
Song, S., Yu, X., Zhang, P. & Dai, H. Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy. J. Diabetes Comp. 34(9), 107641 (2020).
doi: 10.1016/j.jdiacomp.2020.107641
Mohapatra, A., Sudharshan, S., Majumder, P. D., Sreenivasan, J. & Raman, R. Clinical profile and ocular morbidities in patients with both Diabetic Retinopathy and Uveitis. Ophthalmol. Sci. 100511. (2024).
Kwon, J. & Sung, K. R. Effect of preoperative intravitreal bevacizumab on the surgical outcome of neovascular glaucoma at different stages. J Ophthalmol. 2017. (2017).
Aref, A. A. Current management of glaucoma and vascular occlusive disease. Curr. Opi. Ophthalmol. 27(2), 140–145 (2016).
doi: 10.1097/ICU.0000000000000239
Al Sarireh, F., Alrawashdeh, H. M., Al Zubi, K. & Al Salem, K. Role of bevacizumab intraocular injection in the management of neovascular glaucoma. Int. J. Ophthalmol. 14(6), 855 (2021).
doi: 10.18240/ijo.2021.06.10
pubmed: 34150540
pmcid: 8165625
Saito, Y. et al. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am. J. Ophthalmol. 149(6), 964–972 (2010). e961.
doi: 10.1016/j.ajo.2010.01.008
pubmed: 20381786
Appelros, P., Stegmayr, B. & Terént, A. Sex differences in stroke epidemiology: a systematic review. Stroke. 40(4), 1082–1090 (2009).
doi: 10.1161/STROKEAHA.108.540781
pubmed: 19211488
Sanborn, G., Symes, D. & Magargal, L. Fundus-iris fluorescein angiography: evaluation of its use in the diagnosis of rubeosis iridis. Ann. Ophthalmol. 18(2), 52–58 (1986).
pubmed: 2420247
Sia, P. I., Wood, J. P., Chidlow, G. & Casson, R. Creatine is neuroprotective to retinal neurons in vitro but not in vivo. Invest. Ophthalmol. Vis. Sci. 60(13), 4360–4377 (2019).
doi: 10.1167/iovs.18-25858
pubmed: 31634394